Journal of Biomedicine and Biosensors, 6(3):1–8, Jul-Sep: 2026.
DOI: https://doi.org/10.58613/jbb631

Journal of Biomedicine and Biosensors
ISSN (Online): 2583-3170

Journal homepage: https://gpub.org/journal-details.php?journal-id=45

Review Article

The Relationship Between Pathogenic Bacteria and the Immune System from Infection to Disease

Shahrabanawah Mahdi Yasin[1*] **and Alaa Mohammed Hussein**[2]

[1]*Department of Radiology, College of Health and Medical Technology, University of Alkafeel, Najaf, Iraq.*
[2]*Department of Medical Laboratory, College of Health and Medical Technology, University of Alkafeel, Najaf, Iraq.*
[*]*Corresponding author: shahrbanawih@alkafeel.edu.iq*

Article Info

Keywords: *Pathogenic microorganisms, Immune, Virulence factors, Pathways, Immune memory.*

Received: *20.06.2026;*
Accepted: *30.07.2026;*
Published: *05.08.2026*

Abstract

Disease progression and infection outcomes are influenced by the complex interactions between pathogenic microorganisms and the host immune system. The dynamic interaction between host immune responses and bacterial virulence factors is examined in this study, with a focus on immune evasion, modulation, and dysregulation mechanisms. Developing innovative treat. The proper synchronization of several signaling pathways is necessary for host defense against microbial infections. These pathways start an inflammatory cascade that includes leukocyte recruitment to the infection site, activation of antimicrobial effector mechanisms, and induction of an adaptive immune response that facilitates infection clearance and long-term immune memory. They are set off by the innate immune system's recognition of conserved microbial molecules.

1. Introduction

One of the leading causes of disease and mortality in the globe is pathogenic microorganisms [1]. Whether exposure results in acute infection, chronic illness, or asymptomatic colonization depends on how these microbes interact with the host's immune system [2]. The immune response has two sides: it is necessary for the removal of microorganisms, but when it is dysregulated [3], it can also cause tissue harm. The goal of this review is to summarize the state of knowledge on the interactions between pathogenic bacteria and the innate and adaptive arms of the immune system, emphasizing important instances and implications for therapeutic intervention [4].

2. Overview of the Host Immune System in Bacterial Infections

Innate Immune Response

The initial line of defense is the innate immune system, which includes soluble mediators like complement proteins and cytokines, cellular components like neutrophils, dendritic cells, and macrophages, as well as physical barriers like skin and mucosa [5]. Pathogen-associated molecular patterns (PAMPs) are conserved microbial motifs that are detected by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs) [6]. In addition to instructing adaptive immunity, innate recognition and early inflammation

establish the scene for containment or progression; these systems operate within minutes to days [7]. Later disease is significantly influenced by early faults, over activation, or pathogen manipulation [8].

Pattern recognition After identifying conserved microbial compounds, host pattern recognition receptors initiate inflammatory signaling that attracts leukocytes and initiates antimicrobial programs. Mechanisms of effectors Antimicrobial peptides, mucosal secretions, phagocytosis, and oxidative death prevent bacteria from multiplying at entry points [9]. Regulations and controls Endogenous regulators [10], including SOCS proteins, regulate TLR-driven and cytokine/JAK-STAT responses, their induction influences the degree of inflammation and can change the course of infection.

Clinical relevance [11], the severity of a disease can be influenced by deregulated innate reactions, which might harm tissue or fail to confine microorganisms [12].

Adaptive Immune Response

Through B and T cells, the adaptive immune system offers memory and specificity [13]. Opsonization, cytotoxic T-cell responses, and antibody-mediated neutralization are essential for pathogen removal and long-term defense [14]. However, autoimmune or inflammatory pathologies might be exacerbated by deregulation of these responses [15]. Following innate activation, antigen-specific clearance and memory are provided by adaptive responses; latter stages of long-lasting protection depend on antigen presentation and lymphocyte activation [16]. Adaptive immunity's ability to eradicate infection depends on the characteristics of the pathogen and previous immunity. CD8 T cells, which in turn coordinate macrophage activation and cellular death [17].

Antibodies that neutralize poisons, opsonize bacteria for phagocytosis, and prevent adhesion at mucosal surfaces (including IgA at mucosa) are produced by humeral responses B cell activation. Formation of Memory When a resolution is successful [18], memory B and T cells are produced, which accelerate subsequent reactions to the same pathogen. Restrictions on variety Rapid phenotypic alterations and antigenic diversity in bacteria can compromise adaptive recognition and allow for persistence or reinfection [19].

Bacterial Strategies for Immune Evasion and Modulation

To evade host defenses, pathogenic bacteria have developed a variety of strategies, such as Modification of surface antigens (eg Neisseria gonorrhoeae phase variation) to avoid immune identification [20]. The formation of capsules or anti-phagocytic proteins (Streptococcus pneumoniae) inhibits phagocytosis, Effector protein release through Type III or Type IV secretion systems (Salmonella, Yersinia) interferes with signaling pathways [21], Expression of the enzymes catalase and superoxide dismutase (Mycobacterium tuberculosis) confers resistance to oxidative death and Cytokine response modification: inflammatory signaling may be suppressed or hyper activated to promote persistence [22].

Through complement subversion, active immune suppression, intracellular niches, and structural barriers, bacteria circumvent and alter host immunity [23]. Biofilm development, polysaccharide capsules and surface polymers, intracellular survival / phagosome manipulation, and complement regulator recruitment or inhibition are the main tactics [24].

Biofilm formation

The multicellular, matrix-embedded community that biofilms form significantly alters the way bacteria interact with antimicrobials and host immunity. Biofilm cells' matrix and altered physiology restrict immune access, suppress neutrophil activity, and encourage persistent infections that are resistant to therapy [25]. Extracellular matrix barrier Biofilm extracellular polymeric substances prevent antibiotics and host effectors from penetrating bacteria and physically protect them from antibodies and phagocytes [26]. Neutrophil and NET evasion Biofilms can produce substances that counteract neutrophil extracellular traps, impede efficient phagocytosis, and hinder neutrophil killing [27].

Exclusion of opsonic and complement Innate immunity clearance is decreased by dense biofilm structure and matrix components, which also lessen complement deposition and opsonization on embedded cells. Both chronicity and immunologi skewing Biofilms have the ability to alter local adaptive responses, such as skewing T-cell responses, which can result in a standoff that causes a chronic, ongoing infection [28].

Capsule and surface polymers

Widespread, surface-expressed barriers that directly obstruct innate and adaptive identification include polysaccharide capsules and other surface polymers [29]. In addition to masking pathogen-associated genetic patterns and reducing opsonization [30], capsules play a significant role in determining invasive potential and vaccine design issues. Inhibiting antibody and complement-mediated opsonization, anti phagocytic coating capsules and surface polysaccharides hinder neutrophil and macrophage uptake [31]. PAMP masking Bacterial ligands are concealed from pattern recognition receptors by thick surface polymers, which reduces quick innate activation. Variations in virulence and serotype Virulence, immunological recognition, and vaccine methods are all impacted by capsule composition and serotype (particularly for pathogens like Klebsiella and pneumococcus) [32].

Dependency on surface polymers To survive on host surfaces and devices, several species (like S. epidermis) rely mostly on surface polymers and biofilm development [33].

Intracellular survival strategies

In order to persist inside host cells, many infections either adopt niches that conceal them from humeral effectors or interfere with regular phagocyte death routes [34]. In addition to protecting bacteria from external immune systems, intracellular residence modifies adaptive responses and antigen presentation.

Stop the maturation of phagosomes Effective intracellular infections maintain a permissive vacuole for replication by preventing phagosome - lysosome fusion [35].

In order to increase intracellular survival, bacteria that neutralize oxidative death can hinder the respiratory burst and withstand antimicrobial peptides within phagosomes [36]. Evacuate to the cytosol or eliminate phagosomes Some infections multiply in the cytosol, where various immunological restrictions are in effect, by rupturing or evading phagosomal membranes [37].

Inhibit antigen presentation and activation Macrophage activation and antigen presentation pathways can be disrupted by intracellular infections, which can reduce adaptive responses. Survival in phagosomes of extracellular pathogens Certain extracellular pathogens for example S. aureus are also able to persist within phagosomes in some host cells, contributing to persistence and dissemination [38].

Complement interference and regulatory hijacking

By generating complement-inhibitory chemicals and attracting host complement regulators to their surface, bacteria target the complement system [39]. By reducing opsonization, the production of chemo attractants, and the creation of membrane assault complexes, these mechanisms promote invasion and survival. Complement inhibitor secretion Certain bacteria release proteins that directly block complement activation processes, which lowers neutrophil recruitment and deposition [23].

Recruitment of host regulators in order to suppress complement activation locally and avoid opsonization pathogens attach host complement regulatory proteins (such as factor H and associated molecules) to their surface [40]. Decrease in opsonins and MAC bacteria reduce the production of membrane attack complexes which are crucial for gram-negative bacteria, and restrict opsonic tagging for phagocytosis by taking over regulators or proteolytically breaking down complement components [23]. Relevance of vaccines and therapies Because of their function in survival and pathogenicity, surface complement-evasion molecules are frequently immunogenic and serve as targets for vaccine or treatment development [41].

Immunopathology When Defense Becomes Damage

The pathophysiology of disease may be influenced by an overreaction or protracted immune response [42]. Among the examples are cytokine storm, or septic shock brought on by an excessive release of cytokines. tissue damage in long-term infections such gastritis brought on by Helicobacter pylori. Molecular mimicry between bacterial antigens and host tissues causes autoimmunity [43]. One of the key challenges in controlling bacterial infections is maintaining good immunity while causing the least amount of collateral damage.

Through self-reactive antibodies and immune complexes, hypersensitive cell reactions, chronic inflammation, and quick systemic cytokine overproduction, immune defenses damage tissue when control fails or responses overshoot. These processes bring in complement, proteases, and cytotoxic cells, which kill host tissue [44].

Immune damage overview

Innate and adaptive effectors are used by the immune system to neutralize threats, but when they are misused or left unchecked, they can also damage host tissue [45]. Cellular cytotoxicity, the actions of complement and antibodies, the release of proteases and oxidants, and the inability to resolve inflammation are the causes of damage. Neutrophils, macrophages, complement, and antibodies are important effectors that destroy microorganisms but, when triggered improperly, can digest or lyse host tissues [23].

Chronic tissue damage and the persistence of harmful responses are made possible by regulatory failure, which is the lack of checks on inflammation and adaptive responses [46].

Autoimmunity and immune complexes

When self-tolerance fails and adaptive responses target host antigens, autoimmunity damages tissue; one such mechanism is the creation and deposition of antigen - antibody complexes [47]. These complexes cause local inflammation and structural damage by concentrating immunological activation in tissues. Antigen neutralization, opsonization antibody-dependent cellular cytotoxicity, and complement activation are examples of autoantibody functions that can be harmful when directed against one self [48]. Immune complex deposition in organs (for example kidneys in lupus nephritis) provokes local complement activation and inflammatory cell recruitment that drive organ damage. Immune complex deposition is followed by neutrophil recruitment and damage neutrophils are attracted to complexes release proteases and reactive oxygen species, and start the cascade that destroys tissue [49].

Hypersensitivity mechanisms

Maladaptive immune responses that cause tissue damage are known as hypersensitivity reactions, and both cell-mediated and antibody-mediated kinds are significant in immunopathology [50]. Different forms of hypersensitivity activate different cytokine milieus and effectors, resulting in distinctive damage patterns [51]. In certain panniculitis vasculitis, and nephritis lesions type III immune complex interactions result in inflammation where complexes lodge draw neutrophils, and produce complement-mediated damage. Antigen-specific T cells and macrophage activation cause type IV delayed type hypersensitivity which promotes macrophage-mediated cytotoxicity and can quickly damage parenchymal cells and nerves [52]. Clinical patterns can be explained by changes in cytokine signatures. For instance reversal DTH reactions exhibit increases in IL-1, TNF, IL-2, and IFN-γ, whereas immune-complex reactions exhibit increases in IL-6, IL-8, and IL-10, connecting the cytokine milieu to recruited effectors and subsequent harm [53].

Chronic inflammation and cytokine storm

While cytokine storms are sudden, high-amplitude cytokine surges that quickly damage organs, persistent or deregulated immune activation results in continuous cytokine production that remodels and destroys tissue over months to years [54]. Proinflammatory mediators are shared by both, but their clinical courses and timescales are different. Unresolved inflammation or autoimmune disease activity causes chronic cytokine-driven damage, which can cause fibrosis, loss of function, and episodic or gradual tissue death [55]. Supra physiological, systemic elevations of cytokines (typically IL-1, IL-6, IFN-γ, TNF, and GM-CSF) that result in extensive vascular leakage cell death and multi organ

failure spanning hours to days are characteristics of cytokine storms. Blocking important pro-inflammatory cytokines or upstream activators can lessen tissue damage, according to shared therapeutic implications.

However, effective intervention requires that treatment be tailored to the particular inflammatory end type and timeframe [56].

Implications for Therapy and Vaccine Development

Immune modulatory treatments that reduce detrimental inflammation while maintaining antibacterial defense are designed with a better understanding of bacteria–immune interactions [57].

Vaccines of the next generation that improve mucosal immunity or target immune evasion mechanisms. antibiotic resistance-preventing host-directed treatments that boost innate defenses [58].

While adjuvants and monoclonal biologics aid in overcoming immune evasion, mRNA vaccines and antigen focused platforms can neutralize bacterial virulence and reduce pathology targeting biofilms or metabolic pathways enhances immunogenicity and clearance in conjunction with vaccinations and treatments [59].

mRNA and antigen choices

In preclinical bacterial models mRNA platforms can express immune evasion determinants or conserved virulence to trigger protective responses and decrease disease [60]. Animal survival and vaccination immunogenicity can be increased by designing vaccines that target secretory systems or immune-evasion loci that have been eliminated [61]. Preclinical research demonstrated the effectiveness of mRNA vaccines expressing a bacterial type III secretion antigen by improving mouse survival, reducing lung bacterial burden, and reducing lung pathology following challenge [62].

Adjuvants and immune modulation

Adjuvants can help overcome bacterial suppression of host responses; they should be chosen to enhance protective arms of immunity without exacerbating harmful inflammation [63]. Because bacterial immune modulators may unintentionally have pro inflammatory or antigenic effects careful selection and safety assessment are necessary [64].

Improve well-rounded answers To achieve opsonic phagocytic activity and clearance while reducing harmful inflammation, use adjuvants that support both efficient humeral and cellular responses [65]. Restore responsiveness to vaccine antigens that bacteria might normally down modulate by using formulations that enhance antigen presentation or override suppressive signals [61]. Caution for safety Human adverse reactions anaphylaxis and inflammation caused by native bacterial immune modulating proteins that were repurposed as therapies were connected to pre-existing anti bacterial antibodies, highlighting safety and immunogenicity problems for immune-modulator use. Whether adjuvants will increase protection without enhancing disease can be predicted by empirical and translational testing in models that mimic immune logical evasion aged hosts immune suppressed conditions [66].

Monoclonal antibodies and biologics

When vaccination protection is inadequate, monoclonal antibodies and other biologics can improve opsonic phagocytosis, neutralize virulence factors, and act as adjuvants [63]. Although preclinical and translational studies demonstrate proof of concept they also draw attention to the difficulties posed by host pre existing immunity and bacterial immune evasion [67].

Reduce the virulence Biologics based on antibodies can disrupt pathogenic pathways and facilitate clearance by targeting surface or secreted virulence factors [68]. Opsonization and complementarity Candidate antibodies should be tested for functional opsonic phagocytic activity in the context of bacterial complement-evasion systems, as their effectiveness may rely on defeating these evasion techniques. Integration with other tools. In situations when single therapies are ineffective, antibodies can be used in conjunction with antibiotics, anti-biofilm agents, or vaccinations to improve clearance [69]. Immunogenicity risk Pre existing host antibodies and possible hypersensitivity reactions must be taken into consideration when using bacterial proteins or fragments as treatments [70].

Focusing on metabolism and biofilms

Therapeutics and vaccinations that interfere with biofilms and metabolic adaptations [71]. Two key bacterial tactics for persistence and immune avoidance-can increase clearance and lessen immunopathology. Vaccines that contain biofilm or metabolic antigens and direct anti-biofilm drugs are both effective complimentary strategies [72]. Vaccination adjuncts Outer membrane vesicles and other non replicative particle antigens are interesting vaccination candidates because they contain several bacterial components and can boost protection against secreted and biofilm-associated antigens. Metabolic therapies Bacteria can be made more susceptible to host clearance and work in concert with immune systems by focusing on bacterial metabolic pathways that promote persistence or immune resistance [73].

3. Conclusions

The immune system and pathogenic microorganisms have a dynamic, intricate connection that involves balancing attack and defense. Advances in our knowledge of these processes pave the way for novel therapies and prophylactics that transcend conventional antibiotics.

Recommendations

New facets of bacterial–host interactions are being revealed by developing disciplines including immune metabolism, microbiome research, and systems immunology.

Personalized immunotherapeutic methods against bacterial infections may be made possible by integrating omics data with clinical outcomes.

Article Information

Author Contributions: S.M.Y. - Conceptualization, Data curation, Writing – original draft, Writing – review & editing, Supervision; A.M.H. - Formal analysis.

Funding / Financial Support: The authors received no external funding.

Conflict of Interest: The authors declare no competing interests.

Disclaimer (Artificial Intelligence): The author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.), and text-to-image generators have been used during writing or editing of manuscripts.

References

[1] P. Sarmah, M. M. Dan, D. Adapa, and T. K. Sarangi. A review on common pathogenic microorganisms and their impact on human health. *Electronic Journal of Biology*, 14(1):50–58, 2018.

[2] A. Casadevall and L. A. Pirofski. Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease. *Infection and immunity*, 68(12):6511–6518, 2000.

[3] M. Cao, G. Wang, and J. Xie. Immune dysregulation in sepsis: experiences, lessons and perspectives. *Cell death discovery*, 9(1):465, 2023.

[4] C. Campbell, M. R. Kandalgaonkar, R. M. Golonka, B. S. Yeoh, M. Vijay-Kumar, and P. Saha. Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy. *Biomedicines*, 11(2):294, 2023.

[5] W. D. M. Cruvinel, D. Mesquita Júnior, J. A. P. Araújo, T. T. T. Catelan, A. W. S. D. Souza, N. P. D. Silva, and L. E. C. Andrade. Immune system: Part I. Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. *Revista brasileira de reumatologia*, 50:434–447, 2010.

[6] K. Wicherska-Pawłowska, T. Wróbel, and J. Rybka. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. *International journal of molecular sciences*, 22(24):13397, 2021.

[7] T. Monie. *The innate immune system: a compositional and functional perspective*. Academic Press, 2017.

[8] E. Gomez-Diaz, M. Jorda, M. A. Peinado, and A. Rivero. Epigenetics of host–pathogen interactions: the road ahead and the road behind. *PLoS pathogens*, 8(11):e1003007, 2012.

[9] J. D. Aberdein, J. Cole, M. A. Bewley, H. M. Marriott, and D. H. Dockrell. Alveolar macrophages in pulmonary host defence–the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. *Clinical & Experimental Immunology*, 174(2):193–202, 2013.

[10] A. L. Abatayo and J. Lynham. Endogenous vs. exogenous regulations in the commons. *Journal of Environmental Economics and Management*, 76:51–66, 2016.

[11] M. Croes, B. C. van der Wal, and H. C. Vogely. Impact of bacterial infections on osteogenesis: evidence from in vivo studies. *Journal of Orthopaedic Research*, 37(10):2067–2076, 2019.

[12] C. Abraham and R. Medzhitov. Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology*, 140(6):1729–1737, 2011.

[13] G. Natoli and R. Ostuni. Adaptation and memory in immune responses. *Nature immunology*, 20(7):783–792, 2019.

[14] R. M. Zinkernagel and H. Hengartner. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. *Immunological reviews*, 211(1):310–319, 2006.

[15] M. Frieri. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. *Annals of Allergy, Asthma & Immunology*, 90(6):34–40, 2003.

[16] D. A. Cronkite and T. M. Strutt. The regulation of inflammation by innate and adaptive lymphocytes. *Journal of immunology research*, 2018(1):1467538, 2018.

[17] F. R. Shepherd and J. E. McLaren. T cell immunity to bacterial pathogens: mechanisms of immune control and bacterial evasion. *International journal of molecular sciences*, 21(17):6144, 2020.

[18] M. E. Lamm. Interaction of antigens and antibodies at mucosal surfaces. *Annual review of microbiology*, 51(1):311–340, 1997.

[19] N. Lam, Y. Lee, and D. L. Farber. A guide to adaptive immune memory. *Nature Reviews Immunology*, 24(11):810–829, 2024.

[20] M. Virji. Pathogenic neisseriae: surface modulation, pathogenesis and infection control. *Nature Reviews Microbiology*, 7(4):274–286, 2009.

[21] C. J. Hyams. The role of the Streptococcus pneumoniae capsule in interactions with complement and phagocytes (Doctoral dissertation, UCL (University College London), 2010.

[22] M. D. Shastri, S. D. Shukla, W. C. Chong, K. Dua, G. M. Peterson, R. P. Patel, P.M. Hansbro, R. Eri, and R.F. O'Toole. Role of oxidative stress in the pathology and management of human tuberculosis. *Oxidative medicine and cellular longevity*, 2018(1):7695364, 2018.

[23] E. Bjanes and V. Nizet. More than a pore: nonlytic antimicrobial functions of complement and bacterial strategies for evasion. *Microbiology and Molecular Biology Reviews*, 85(1):1110–1128, 2021.

[24] R. E. Kasuboski-Polando. *The role of pattern recognition receptors in host cell signaling and phagosome maturation during infection with Leishmania*. University of Notre Dame, 2009.

[25] V. Gordon, L. Bakhtiari, and K. Kovach. From molecules to multispecies ecosystems: the roles of structure in bacterial biofilms. *Physical biology*, 16(4):041001, 2019.

[26] D. Campoccia, S. Ravaioli, R. Mirzaei, G. Bua, M. Daglia, and C. R. Arciola. Interactions of neutrophils with the polymeric molecular components of the biofilm matrix in the context of implant-associated bone and joint infections. *International Journal of Molecular Sciences*, 24(23):17042, 2023.

[27] A. L. Ríos-López, G. M. González, R. Hernández-Bello, and A. Sánchez-González. Avoiding the trap: Mechanisms developed by pathogens to escape neutrophil extracellular traps. *Microbiological research*, 243:126644, 2021.

[28] K. Lee. Bacterial biofilm interactions with human immune cells (Doctoral dissertation, University of Nottingham (United Kingdom)). 2022.

[29] S. R. Perera, A. S. Sokaribo, and A. P. White. Polysaccharide vaccines: a perspective on non-typhoidal Salmonella. *Polysaccharides*, 2 (3):691–714, 2021.

[30] A. Häder, S. Schäuble, J. Gehlen, N. Thielemann, B. C. Buerfent, V. Schüller, T. Hess, T. Wolf, J. Schröder, M. Weber, K. Hünniger, J. Löffler, S. Vylkova, G. Panagiotou, J. Schumacher, and O. Kurzai. Pathogen-specific innate immune response patterns are distinctly affected by genetic diversity. *Nature Communications*, 14(1):3239, 2023.

[31] N. Sathyamoorthy and M. D. Dhanaraju. Shielding therapeutic drug carriers from the mononuclear phagocyte system: a review. *Critical Reviews in Therapeutic Drug Carrier Systems*, 33(6), 2016.

[32] K. A. Geno, G. L. Gilbert, J. Y. Song, I. C. Skovsted, K. P. Klugman, H.B. Jones, C. Konradsen, and M.H. Nahm. Pneumococcal capsules and their types: past, present, and future. *Clinical microbiology reviews*, 28(3):871–899, 2015.

[33] B. Gottenbos, H. C. van der Mei, and H. J. Busscher. Initial adhesion and surface growth of Staphylococcus epidermidis and Pseudomonas aeruginosa on biomedical polymers. *Journal of Biomedical Materials Research*, 50(2):208–214, 2000.

[34] A. Thakur, H. Mikkelsen, and G. Jungersen. Intracellular pathogens: host immunity and microbial persistence strategies. *Journal of immunology research*, 2019(1):1356540, 2019.

[35] H. J. Lee, Y. Woo, T. W. Hahn, Y. M. Jung, and Y. J. Jung. Formation and maturation of the phagosome: a key mechanism in innate immunity against intracellular bacterial infection. *Microorganisms*, 8(9):1298, 2020.

[36] M. B. Hampton and N. Dickerhof. Inside the phagosome: A bacterial perspective. *Immunological reviews*, 314(1):197–209, 2023.

[37] E. Uribe-Querol and C. Rosales. Control of phagocytosis by microbial pathogens. *Frontiers in immunology*, 8:1368, 2017.

[38] G. Weiss and U. E. Schaible. Macrophage defense mechanisms against intracellular bacteria. *Immunological reviews*, 264(1):182–203, 2015.

[39] E. S. Hovingh, B. Van den Broek, and I. Jongerius. Hijacking complement regulatory proteins for bacterial immune evasion. *Frontiers in Microbiology*, 7:2004, 2016.

[40] C. Q. Schmidt, J. D. Lambris, and D. Ricklin. Protection of host cells by complement regulators. *Immunological reviews*, 274(1): 152–171, 2016.

[41] J. Mellors, T. Tipton, S. Longet, and M. Carroll. Viral evasion of the complement system and its importance for vaccines and therapeutics. *Frontiers in immunology*, 11:1450, 2020.

[42] P. Sarmah, M. M. Dan, D. Adapa, and T. K. Sarangi. A review on common pathogenic microorganisms and their impact on human health. *Electronic Journal of Biology*, 14(1):50–58, 2018.

[43] A. R. S. Aljohani. Detection and Molecular characterization of Different Helicobacter Pylori Strains Isolated in Almadinah ALmunawarah Region (Doctoral dissertation, Department of Biological Sciences Faculty of Science, King Abdulaziz University Jeddah-Saudi Arabia 1442). 2021.

[44] R. Straub. *The origin of chronic inflammatory systemic diseases and their sequelae*. Academic press, 2015.

[45] M. J. Spiering. Primer on the immune system. *Alcohol research: current reviews*, 37(2):171–175, 2015.

[46] R. Medzhitov. The spectrum of inflammatory responses. *Science*, 374(6571):1070–1075, 2021.

[47] E. Mezgebu, A. Aliy, and T. Worku. Autoimmunity and immune tolerance: A review. *Microbiol. Res. Int.*, 11:23–25, 2023.

[48] J. Stewart and D. M. Weir. Innate and acquired immunity. *Medical microbiology*, 9:1–28, 2012.

[49] T. N. Mayadas, G. C. Tsokos, and N. Tsuboi. Mechanisms of immune complex–mediated neutrophil recruitment and tissue injury. *Circulation*, 120(20):2012–2024, 2009.

[50] M. Jutel, I. Agache, M. Zemelka-Wiacek, M. Akdis, T. Chivato, S. Del Giacco, P. Gajdanowicz, I.E. Gracia, L. Klimek, A. Lauerma, M. Ollert, L. O'Mahony, J. Schwarze, M.H. Shamji, I. Skypala, O. Palomares, O. Pfaar, M.J. Torres, J.A. Bernstein, A.A. Cruz, S.R. Durham, S.J. Galli, R.M. Gómez, E. Guttman-Yassky, T. Haahtela, S.T. Holgate, K. Izuhara, K. Kabashima, D.E. Larenas-Linnemann, E. von Mutius, K.C. Nadeau, R. Pawankar, T.A.E. Platts-Mills, S.H. Sicherer, H.S. Park, S. Vieths, G. Wong, L. Zhang, M.B. Bilò, and C.A. Akdis. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. *Allergy*, 78(11):2851–2874, 2023.

[51] I. J. Elenkov and G. P. Chrousos. Stress, cytokine patterns and susceptibility to disease. *Best Practice & Research Clinical Endocrinology & Metabolism*, 13(4):583–595, 1999.

[52] T. A. Newman, S. T. Woolley, P. M. Hughes, N. R. Sibson, D. C. Anthony, and V. H. Perry. T-cell-and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. *Brain*, 124(11):2203–2214, 2001.

[53] F. O. Martinez, A. Sica, A. Mantovani, and M. Locati. Macrophage activation and polarization. *Front biosci*, 13(13):453–461, 2008.

[54] J. R. Zierath. Major advances and discoveries in diabetes-2019 in review. *Current diabetes reports*, 19(11):118, 2019.

[55] D. A. McBride, M. D. Kerr, N. C. Dorn, D. A. Ogbonna, E. C. Santos, and N. J. Shah. Triggers, timescales, and treatments for cytokine-mediated tissue damage. *European medical journal Innovations*, 5(1):52, 2020.

[56] R. Vella, D. Panci, F. Carini, G. Malta, S. Vieni, S. David, G.D. Albano, M. Puntarello, S. Zerbo, and A. Argo. Cytokines in sepsis: a critical review of the literature on systemic inflammation and multiple organ dysfunction. *Frontiers in Immunology*, 16, 2025. Article 1682306.

[57] R. E. Hancock, A. Nijnik, and D. J. Philpott. Modulating immunity as a therapy for bacterial infections. *Nature Reviews Microbiology*, 10(4):243–254, 2012.

[58] M. Worley. Immune evasion and persistence in enteric bacterial pathogens. *Gut Microbes*, 15(1):2163839, 2023.

[59] I. N. Weerarathna, E. S. Doelakeh, L. Kiwanuka, P. Kumar, and S. Arora. Prophylactic and therapeutic vaccine development: advancements and challenges. *Molecular Biomedicine*, 5(1):57, 2024.

[60] N. Pardi and F. Krammer. mRNA vaccines for infectious diseases—advances, challenges and opportunities. *Nature Reviews Drug Discovery*, 23(11):838–861, 2024.

[61] G. N. Medina and F. Diaz San Segundo. Virulence and immune evasion strategies of FMDV: implications for vaccine design. *Vaccines*, 12(9):1071, 2024.

[62] A. Khlebnikova, A. Kirshina, N. Zakharova, R. Ivanov, and V. Reshetnikov. Current progress in the development of mRNA Vaccines against bacterial infections. *International Journal of Molecular Sciences*, 25(23):13139, 2024.

[63] V. A. Correa, A. I. Portilho, and E. De Gaspari. Vaccines, adjuvants and key factors for mucosal immune response. *Immunology*, 167 (2):124–138, 2022.

[64] J. G. Sathish, S. Sethu, M. C. Bielsky, L. De Haan, N. S. French, K. Govindappa, J. Green, C.E. Griffiths, S. Holgate, D. Jones, I. Kimber, J. Moggs, D.J. Naisbitt, M. Pirmohamed, G. Reichmann, J. Sims, M. Subramanyam, M.D. Todd, J.W. Van Der Laan, R.J. Weaver, and B.K Park. Challenges and approaches for the development of safer immunomodulatory biologics. *Nature Reviews Drug Discovery*, 12(4):306–324, 2013.

[65] B. Sundaresh. Bacterial multi-omics profiling reveals novel routes to immune evasion and disease outcome: Towards targeted therapeutic strategies (Doctoral dissertation, Boston College). 2023.

[66] S. Jani, C. D. Church, and P. Nghiem. Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas. *Frontiers in immunology*, 14, 2023. Article 1172913.

[67] I. Frost, H. Sati, P. Garcia-Vello, M. Hasso-Agopsowicz, C. Lienhardt, V. Gigante, and P. Beyer. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. *The Lancet Microbe*, 4(2): e113–e125, 2023.

[68] F. Vacca, C. Sala, and R. Rappuoli. Monoclonal antibodies for bacterial pathogens: mechanisms of action and engineering approaches for enhanced effector functions. *Biomedicines*, 10(9):2126, 2022.

[69] J. Han and A. Poma. Molecular targets for antibody-based anti-biofilm therapy in infective endocarditis. *Polymers*, 14(15):3198, 2022.

[70] M. Baker, H. M. Reynolds, B. Lumicisi, and C. J. Bryson. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. *Self/nonself*, 1(4):314–322, 2010.

[71] U. Römling and C. Balsalobre. Biofilm infections, their resilience to therapy and innovative treatment strategies. *Journal of internal medicine*, 272(6):541–561, 2012.

[72] A. Loera-Muro, A. Guerrero-Barrera, Y. Tremblay D. N., S. Hathroubi, and C. Angulo. Bacterial biofilm-derived antigens: A new strategy for vaccine development against infectious diseases. *Expert Review of Vaccines*, 20(4):385–396, 2021.

[73] I. C. Acosta. The intersection between bacterial metabolism and innate immunity. *Journal of Innate Immunity*, 15(1):782–803, 2023.